on well be at towards progress our Exelixis cover will to our I highlights Today, East as cabozantinib organizational June. afternoon. presented of upcoming Good progress the in pipeline East, to data Coast, P.J. you, meeting and ASCO Thank our expansion the as
As expanding our we early developing development presence we organization. talent to Philadelphia support to year, we announced as a seek this Greater both in on are coasts access
and signing progress July made this which last King occupy office-based lease space have hold quarterly we We for by since to employees. year the a which term in including of of expect update, Pennsylvania XXX approximately can intermediate Prussia,
as development recruitment singular area. improve hiring of organization close the site hubs, have across excited operating of in a square identified presence Prussia opportunity to build-to-suit cancer. by bicoastal term by focused have with King our on mission in to two of one an I'm developing also XXX,XXX We patients of the the campaign a Philadelphia King in awareness medicines roles we intermediate lives to team presence to raise create of proximity within supported ongoing approximately open feet long-term begun the potential the of space in our biotechnology Prussia, to and
Turning remain now our year. three this with track registrational to We for on beginning on our cabozantinib Phase trials. III pipeline, readouts an update
in cancer nivolumab in atezolizumab metastatic non-small are lung readout for cabozantinib is with cell risk evaluating CONTACT-XX carcinoma, and in CONTACT-XX, prostate XXXX. in we expected to in castrate-resistant in July. Phase combination this our study We expected cancer second COSMIC-XXX, combination the carcinoma, complete atezolizumab with primary expect cell intermediate and of the experienced endpoint respectively, survival release with enrollment top of renal to in for renal year. results poor in the of and interim for half combination and endpoint CONTACT-XX III cell For readout progression-free line overall An ipilimumab survival PD-X
make on and alternative combination dosing replace it and of an immuno-oncology combination BEMPEG protocol that combination. nivolumab with pipeline our kinase VEGFR in and explored studies. IO MER We is next-generation progress MET, our checkpoint inhibitors several with tyrosine being on combination and is progressing nivolumab-based genitourinary the XLXXX amending molecules. XLXXX, a remove initiated and to study and are registrational recently malignancies We we AXL, continue triplet towards inhibitor to in combinations with triplet
We explore to also with combinations have several partners clinic. progress made agents combination approaches bring additional and with the continue to potential novel novel into
colorectal this Phase first the STELLAR-XXX in initiated be III quarter for Our planned year. non-MSI XLXXX, cancer third-line high second will of and
XBXXX, a study in at studies in activity antibody As continues models data of the reminder, regorafenib, supporting and Thus with first comparison January factor current care. comes has preclinical it our without colorectal which coagulation historical interfering of of cabozantinib cancer observed. conjugate, promising well two no in targets bleeding ASCO-GI far, dose tolerated standard tissue which with events escalation. drug been to controls in were pathway the demonstrated in presented this from
I Phase the escalation now monotherapy XBXXX inhibitor, move combination into expected single dose which has II dose dose for finding of cohort. completion to beginning combinations expansion with an oral of after Phase in safety We cleared initiating level, cohorts determination XLXXX, both and A a dose. our ongoing and agent CDKX is are of evaluation study also
Phase I XLXXX trial open enrollment. the Finally, for now is
clinical second to provide updates XBXXX in Phase this expect XLXXX XLXXX, year. and We half of I for the
oral Finally, checkpoint bladder cabozantinib based two atezolizumab ASCO I'd cabozantinib finding COSMIC-XXX, presentations from three been to that presentations inhibitors previously and like plus alone. five study, of populations highlight have two the or upcoming we of who cell abstracts these. cancer meeting, our the and platinum-based on for are accepted include pleased These the patients signal at distinct chemotherapy, with lung and either cabozantinib other cancer immune received cohorts treated of non-small three in patients multitumor first
study be over And it neck head II cabozantinib of Phase turn in pembrolizumab I'll positive will the that, investigator-sponsored addition squamous cell Peter. of an to the PD-LX carcinoma presented. to and Additionally, with evaluating
